A pleasure (as always) hosting Robert Timmerman for thought provoking and forward thinking considerations in #radonc Houston Methodist MD grand rounds! #PULSAR #CUT

The data have been conflicting re: whether/to what extent RT increases risk of 2nd malignancy in rectal cancer, but % worth counseling pts, particularly w increasing EOCRC. ~5% risk of 2nd pelvic ca (10 yr) ~5-10% for non-pelvic ca Emphasizes importance of continued vigilance

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. Ralph Weichselbaum Sean Pitroda, M.D. Amy L. Cummings, MD PhD doi.org/10.1038/s43018…

First study of ureteral toxicity of mostly (>95%) 5Fx SBRT suggests current constraints (e.g. Timmerman D0.035cc <45 Gy) may be too strict. Only 1/16 pts exceeded D0.1cc >108 Gy EQD2 (~45 Gy/5Fx) and developed late toxicity Great work! #radonc IJROBP - The Red Journal redjournal.org/article/S0360-…

Distant failure after SBRT for oligometastatic disease is a common pattern of progression. Yet, we lack validated post-progression models to guide treatment. We tested whether Distant Metastasis Velocity (DMV) can fill this gap - and validated it across multinational cohorts 🧵

Looking forward to moderating this 🔥 webinar on role of #radiation ☢️ in treating #benign conditions including both #cns 🧠 and #msk 🦴 indications ft. TaritaThomas MD, PhD, MBA and Samuel Chao Join us as we explore these new indications of RT #osteoarthritis #gammaknife as a part of

Congrats to our very own Dr. Sagus Sampath and #radonc teams City of Hope - Department of Radiation Oncology & UTSW Radiation Oncology on providing more prospective evidence in eClinicalMedicine for consolidative RT for advanced EGFRmut NSCLC with modern 3rd gen TKI (osimertinib). Best-in-class median PFS of 35.7 months❗️

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial sciencedirect.com/science/articl… The phase 2 EXTEND trial showed that in patients with oligometastatic #ProstateCancer

🇳🇴 A Norwegian study reveals a significant shift in the intent of radiation therapy treatments for NSCLC over the past decade, with a higher proportion prescribed for cure and less for palliation. #radonc sciencedirect.com/science/articl…

Here are a few facts that all #WCLC25 attendees should know about. #radonc

Excited to discuss the role of radiation therapy in the management of hidradenitis with Shauna Campbell, DO in The Lancet #radonc AHN pubmed.ncbi.nlm.nih.gov/40885579/

Interesting work from the ASTRO Workforce Committee looking to define a standard way to define supply in #radonc pubmed.ncbi.nlm.nih.gov/40962071/ Jason Beckta , definitely want to hear your thoughts!

If you’re a fan of radiation oncology and struggling to figure out why more people don’t celebrate the cancer treatments we deliver, then this editorial might be for you. IJROBP - The Red Journal Sue Yom Neha Vapiwala redjournal.org/article/S0360-…

Multicenter, randomized, sham-controlled trial LDRT vs OA Knee OA were allocated to receive sham irradiation, total 0.3 Gy/6 fractions, or total 3 Gy/6 fractions Endpoint: OMERACT-OARSI response rate at 4 m 70.3% (3 Gy) vs 41.7% (sham) p=0.014 #ASTRO2025

📢 Phase III RCT in locally advanced #OPSCC: proton 💠 vs conventional #radiotherapy 🔆 ❌ No diff. in 12-mo gastrostomy rate, QOL, or swallowing. ⚖️ Similar 2-yr local control & OS (~95%). 👉 High-quality IMRT remains standard; IMPT not required. #ASTRO25 #RadOnc ASTRO

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &

Improved onc outcomes with post-op RT for bladder cancer BART trial by Tata Memorial Hospital Vedang Murthy #ASTRO25 ASTRO

WOW! 🧠METIS trial (n=298) in #lungcancer brain mets: SRS ➕ TTFields ⚡vs SRS alone ✅ TTFields delays intracranial progression (HR 0.72, p=0.044) 📉12-mo progression: 47% vs 59%; ⬆️ with immunotherapy (HR 0.63) ❌No QoL / cognition decline; AEs mild skin #ASTRO25 #RadOnc

Here's why protons for HN cancer might be TORPEDOed: With weight loss, IMPT can get bad, fast. OAR doses go way up: 27% increase for parotid and >100% increase for esophagus by week 2 for bulky tumours. 🔥 Maybe a negative spiral? Worse plan, more weight loss, even worse plan.

The U.S. CBO Congressional Budget Office released "Growth in the 340B Drug Pricing Program" On Sept 2, 2025 cbo.gov/publication/60… For comparison, I made a graph of "Growth in Radiation Oncology #radonc Spending" over the same time period